Phase 1 trial of GD2-SADA: (177)Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma Meeting Abstract
| Authors: | Owonikoko, T. K.; Moser, J. C.; Yoon, J.; Slotkin, E. K.; Dowlati, A.; Ma, V. T.; Dùˆring, M.; Sveistrup, J. |
| Abstract Title: | Phase 1 trial of GD2-SADA: (177)Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 ASCO Annual Meeting |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS3162 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS3162 -- Meeting was also available virtually -- Source: Cinahl |
